Stock Market Reviews

CLSD (Clearside Biomedical, Inc.) News

Get the latest news, insights, and market updates on CLSD (Clearside Biomedical, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
  Compugen (CGEN) delivered earnings and revenue surprises of -14.29% and -76.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 6, 2025 - $CLSD
• Top Midday Gainers
  Abivax (ABVX) shares catapulted 555% amid heavy trading after the company said late Tuesday its inve
  Jul 23, 2025 - $CLSD
• Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
  - XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has granted approval for
  Jul 23, 2025 - $CLSD
• BC-Most Active Stocks
  Gibo Holdings Ltd. 219,016,760 0.0515
  Jul 23, 2025 - $CLSD
• Snowflake initiated, Chipotle upgraded: Wall Street's top analyst calls
  Snowflake initiated, Chipotle upgraded: Wall Street's top analyst calls
  Jul 18, 2025 - $CLSD
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks declined late Friday afternoon with the NYSE Health Care Index falling 0.6% and t
  Jul 18, 2025 - $CLSD
• Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
  - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations - ALPHARETTA, Ga., July 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical compa
  Jul 17, 2025 - $CLSD
• Shareholders in Clearside Biomedical (NASDAQ:CLSD) are in the red if they invested five years ago
  Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. To...
  Jun 28, 2025 - $CLSD
• Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
  - Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the use o
  Jun 17, 2025 - $CLSD
• Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
  Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  May 29, 2025 - $CLSD